Back to Supplement Score
69
SCORE

Chondroitin sulfate (standalone)

Osteoarthritis · Cartilage preservation · Joint space · GAIT trial
Tier 2 — Promising

What it is

A structural glycosaminoglycan that draws water into the joint matrix, providing cushioning and reducing cartilage degradation enzymes (MMP-3, MMP-13). Unlike glucosamine, chondroitin has stronger evidence for slowing structural OA progression rather than just symptom relief. The MOAKS study found 800 mg/day significantly reduced cartilage loss on MRI at 24 months. A 2023 network meta-analysis ranked chondroitin above glucosamine for joint space preservation. Pain relief effect size is modest but comparable to low-dose NSAIDs without the GI risks. European OA guidelines recommend it as a slow-acting drug.

Efficacy
3/5
Safety
5/5
Research
4/5
Onset
2/5
Cost
3/5
Drug-int.
3/5

Dose

800–1,200 mg/day chondroitin sulfate; separate from other supplements; minimum 3-month trial for structural benefits

Time of day & tips

Take with food to minimise mild GI upset in some users. May mildly potentiate warfarin — check with your doctor if on anticoagulants. At least 3 months needed to assess benefit. The structural protective effect is gradual and cumulative — commit to daily use.

Cycling

Safe for continuous long-term use indefinitely. Most benefit from sustained daily use. Stopping reverses structural protection within weeks.

Compare or learn more

Compare with another supplement →
Browse by symptom →
Open the full interactive view →

Educational reference, not medical advice. About · Methodology · Privacy · Terms